目的 探討益腦復(fù)健膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死的臨床療效。方法 選取2019年4月—2021年12月在南陽市第一人民醫(yī)院接受治療的96例急性腦梗死患者，采用信封抽簽法將患者分為對照組和治療組，每組各48例。對照組靜脈滴注依達(dá)拉奉注射液，30 mg溶于150 mL生理鹽水中，半小時內(nèi)滴注結(jié)束，1次/d。治療組在對照組的基礎(chǔ)上口服益腦復(fù)健膠囊，3～4粒/次，3次/d。兩組均治療14 d。觀察兩組臨床療效，比較兩組的神經(jīng)功能缺損情況、腦血流動力指標(biāo)、血液流變學(xué)指標(biāo)和神經(jīng)遞質(zhì)。結(jié)果 治療后，治療組的總有效率為91.67%，高于對照組的總有效率75.00%（P＜0.05）。治療后，兩組美國國立衛(wèi)生研究院卒中量表（NIHSS）評分均顯著下降（P＜0.05），且治療組NIHSS評分明顯低于對照組（P＜0.05）。治療后，兩組大腦動脈血流最大峰值（V_s）、平均流速（V_m）均顯著升高，血管阻力指數(shù)（RI）顯著下降（P＜0.05），治療組V_s、V_m均顯著高于對照組，RI均顯著低于對照組（P＜0.05）。治療后，兩組血小板聚集率、血漿黏度、血細(xì)胞比容、纖維原蛋白均顯著下降（P＜0.05），且治療組血小板聚集率、血漿黏度、血細(xì)胞比容、纖維原蛋白均明顯低于對照組（P＜0.05）。治療后，兩組血清神經(jīng)元特異性烯醇化酶（NSE）、S100β蛋白水平顯著下降（P＜0.05），且治療組血清NSE、S100β蛋白水平顯著低于對照組（P＜0.05）。結(jié)論 益腦復(fù)健膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死具有較好的臨床療效，可減輕神經(jīng)功能缺損，改善機(jī)體血液流變學(xué)，減輕機(jī)體應(yīng)激反應(yīng)，改善神經(jīng)遞質(zhì)水平分泌，具有較好的臨床應(yīng)用價值。

Objective To explore the clinical effect of Yinao Fujian Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (96 cases) with acute cerebral infarction in Nanyang First People’s Hospital from April 2019 to December 2021 were divided into control and treatment groups according to the envelope drawing method, and each group had 48 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into normal saline 150 mL, completed the infusion within half an hour, once daily. Patients in the treatment group were po administered with Yinao Fujian Capsules on the basis of the control group, 3 — 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the neurological deficit, cerebral hemodynamics, hemorheology, and neurotransmitters in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.67%, which was higher than that of the control group (75.00%, P < 0.05). After treatment, the scores of NIHSS in two groups were significantly decreased (P < 0.05), and the scores of NIHSS in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, V_s and V_m in two groups were significantly increased, but RI in two groups was significantly decreased (P < 0.05). V_s and V_m in the treatment group were significantly higher than those in the control group, but RI in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the platelet aggregation rate, plasma viscosity, hematocrit, and fibrinogen in two groups were significantly decreased, and these indexes in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of NSE and S100β protein in two groups were significantly decreased (P < 0.05), and the serum levels of NSE and S100β protein in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Yinao Fujian Capsules combined with Edaravone Injection has a significant effect in treatment of acute cerebral infarction, can reduce the neural function defect, improve the hemorheology of the body, reduce the stress response of the body, and improve the secretion of neurotransmitters, which has good clinical application value.

R971

河南省科技發(fā)展計(jì)劃項(xiàng)目（182102320664）